Saama, a leading provider of AI-based solutions for clinical development and commercialization, announced a new multi-year agreement with Pfizer, a global biopharmaceutical company, to scale up their data review automation and speed up regulatory submissions.

The partnership builds on the success of their previous collaboration, which resulted in Smart Data Quality (SDQ), an AI-powered tool that reduced the time to database lock for Pfizer’s COVID-19 vaccine trials. SDQ will now be applied to more of Pfizer’s global studies, enabling faster and more consistent data review and reconciliation.

In addition, Saama will help Pfizer leverage its new Biometrics Research and Analysis Information Network, a next-generation solution that streamlines statistical programming and biostatistics workflows, digitizes study specifications, and generates submission-ready tables, listings, and figures (TLF) artifacts. This will further reduce regulatory submission timelines across Pfizer’s portfolio and pave the way for more innovation and automation in the future.

Saama’s solutions use the industry’s most advanced technology and AI capabilities to help study teams manage the high volume and variety of clinical trial data. Saama’s platform supports the full spectrum of clinical development, from data collection and standardization to analysis and reporting.

“Saama’s AI-enabled technology platform has proven its ability to improve and accelerate the clinical trial process, and ultimately, to help bring treatments to patients faster,” said Lisa Moneymaker, Chief Technology Officer and Chief Product Officer, Saama. “We are excited to expand our strategic partnership with Pfizer across their global portfolio and to change the way drug development is done to benefit more people around the world.”

“Accelerating analysis and reporting for clinical trials is essential to developing breakthrough medicines,” said Demetris Zambas, Vice President and Global Head Data Monitoring and Management, Pfizer. “We look forward to working with Saama to leverage their cutting-edge, AI-based technologies to enhance the quality and efficiency of data review and reconciliation, and to streamline regulatory submissions across our diverse and complex clinical studies.”